MAP2K7 and malignant peripheral nerve sheath tumor: Efforts to target histone acetylation in a preclinical MPNST model with loss of SUZ12 shrank tumors when combined with MEK inhibition [41], while other DNA methyltransferase inhibitors appear to affect immune surveillance of MPNST [92].